

SUPPLEMENTARY DATA

Table 1 of the supplementary data - Comparative of HRQoL analysis of the patients with FCM infusion at three months follow-up.

Test/Questionnaire	Basal (n = 205)	3 months (n = 52)	P
EQ-5D-3L-mobility, n (%)			
I have no problems walking about	78 (37.7)	22 (42.3)	.842
I have some problems walking about	128 (61.8)	30 (57.7)	.842
I am confined to bed	1 (0.5)	0 (0)	-
EQ-5D-3L-self-care, n (%)			
I have no problems with self-care	150 (72.1)	40 (76.9)	.274
I have some problems washing or dressing myself	50 (24.0)	12 (23.1)	.651
I am unable to wash or dress myself	8 (3.8)	0 (0)	.079
EQ-5D-3L-activities, n (%)			
I have no problems with performing my usual activities	99 (47.8)	23 (44.2)	.843
I have some problems with performing my usual activities	94 (45.4)	28 (53.8)	.844
I am unable to perform my usual activities	14 (6.8)	1 (1.9)	.308
EQ-5D-3L-pain, n (%)			
I have no pain or discomfort	85 (40.9)	19 (36.5)	.839
I have moderate pain or discomfort	103 (49.5)	28 (53.8)	.990
I have extreme pain or discomfort	20 (9.6)	5 (9.6)	.727
EQ-5D-3L-anxiety, n (%)			
I am not anxious or depressed	113 (54.6)	34 (65.4)	.420
I am moderately anxious or depressed	86 (41.5)	16 (30.8)	.410
I am extremely anxious or depressed	8 (3.9)	2 (3.8)	.990
Minnesota Questionnaire			
Q1. Causing swelling in your ankles or legs?	1.53 ± 1.62	1.33 ± 1.39	.569
Q2. Making you sit or lie down to rest during the day?	1.96 ± 1.67	1.88 ± 1.49	.646
Q3. Making your walking about or climbing stairs difficult?	2.93 ± 1.69	2.47 ± 1.78	.179
Q4. Making your working around the house or yard difficult?	2.41 ± 1.82	2.06 ± 1.87	.467
Q5. Making your going places away from home difficult?	2.60 ± 1.83	2.35 ± 2.02	.258
Q6. Making your sleeping well at night difficult?	1.98 ± 1.68	1.42 ± 1.75	.113
Q7. Making you relating to or doing things with friends or family difficult?	1.32 ± 1.56	1.21 ± 1.56	.999
Q8. Making you working to earn a living difficult?	1.58 ± 1.97	1.23 ± 1.69	.544
Q9. Making your recreational pastimes, sports, or hobbies difficult?	1.96 ± 1.95	1.47 ± 1.68	.550
Q10. Making your sexual activities difficult?	1.68 ± 1.92	1.69 ± 1.92	.327

Q11. Making you eat less of the foods you like?	2.03 \pm 1.76	1.79 \pm 1.89	.634
Q12. Making you short of breath?	2.19 \pm 1.75	1.74 \pm 1.73	.885
Q13. Making you tired, fatigued, or low on energy?	2.51 \pm 1.74	1.69 \pm 1.94	.165
Q14. Making your stay in a hospital?	1.30 \pm 1.67	0.92 \pm 1.53	.177
Q15. Costing you money for medical care?	1.32 \pm 1.67	0.96 \pm 1.43	.061
Q16. Giving you side effects from treatments?	1.00 \pm 1.45	0.96 \pm 1.48	.339
Q17. Making you feel you are a burden to your family or friends?	1.25 \pm 1.66	1.29 \pm 1.66	.659
Q18. Making you feel a loss of self-control in your life?	1.48 \pm 1.76	1.45 \pm 1.74	.924
Q19. Making you worry?	2.01 \pm 1.80	1.62 \pm 1.80	.172
Q20. Making it difficult for you to concentrate or remember things?	1.78 \pm 1.71	1.45 \pm 1.61	.334
Q21. Making you feel depressed?	1.66 \pm 1.70	1.27 \pm 1.48	.103
MLHFQ Questionnaire			
Physical dimension	18.4 \pm 10.8	15.9 \pm 10.5	.326
Emotional dimension	8.1 \pm 7.3	7.1 \pm 7.0	.318
Global score	38.4 \pm 26.0	34.9 \pm 25.2	.334

FCM, ferric carboxymaltose; HRQoL, health-related quality of life; MLHFQ,

Minnesota Living with Heart Failure Questionnaire; Q, question number.

There were 31 patients with incomplete basal EQ-5D-3L and Minnesota test and 147 in the 3 months follow-up.

Data are expressed as no. (%) or mean \pm standard deviation.

Table 2 of the supplementary data - Comparative of the characteristics of the patients at three months according to TSAT level.

Characteristics	TSAT < 20 (n = 184)			TSAT ≥ 20 (n = 34)			<i>P</i>
	Basal	3 months	<i>P</i>	Basal	3 months	<i>P</i>	
Age (years)	73.2 (10.6)			75.4 (11.6)			.265
Sex (female), n (%)	96 (52.2)			18 (52.9)			.934
SBP (mmHg)	124.4 (18.9)			126.4 (17.0)			.561
HR (bpm)	69.5 (11.9)			67.1 (11.8)			.279
Functional class, n (%)							.101
NYHA I	4 (2.2)	10 (10.0)	.045	3 (9.1)	20 (16.3)	.001	
NYHA II	141 (79.2)	76 (76.0)		26 (78.8)	95 (77.2)		
NYHA III	33 (18.5)	14 (14.0)		4 (14.6)	8 (6.5)		
NYHA improvement ≥ 1		40 (22.5)			5 (15.2)		.641
NYHA no improvement		133 (74.7)			27 (81.8)		
NYHA deterioration ≥ 1		5 (2.8)			1 (3.0)		
LVEF (%)	44.4 (15.0)			43.7 (15.7)			.805
FCM dose (mg)	951.1 (148.9)			911.8 (193.5)			.180
Theoretical dose, n (%)	82 (44.6)			18 (54.5)			.290
Hb (g/dL)	12.3 (1.5)	12.9 (1.7)	.0001	13.1 (1.4)	13.5 (1.1)	.018	.013
Anemia- n (%)	84 (45.7)			10 (30.3)			.101
MCHC (pg)	28.9 (2.8)	30.3 (2.0)	.0001	30.8 (1.8)	31.7 (1.8)	.012	.0001
MCV (fL)	90.1 (7.9)	94.2 (5.4)	.0001	93.2 (12.5)	98.7 (5.3)	.002	.064
Serum Fe (mcg/dL)	47.1 (16.2)	79.9 (31.8)	.0001	89.8 (21.1)	90.8 (23.9)	.845	.0001
Transferrin (mg/dL)	284.5 (60.8)	232.3 (50.1)	.0001	248.9 (41.5)	210.6 (40.0)	.0001	.001
Ferritin (ng/mL)	64.9 (79.3)	280.1 (393.2)	.0001	108.5 (122.3)	278.8 (124.7)	.0001	.008
TSAT (%)	11.9 (4.1)	24.0 (11.1)	.0001	25.8 (6.4)	29.4 (9.6)	.021	.0001
Absolute ID, n (%)	151 (82.1)	27 (19.4)	.0001	23 (67.6)	1 (4.2)	.0001	.001
NT-proBNP (pg/mL)	4754.0 (6577.4)	3282.4 (3611.8)	.001	3585.4 (4796.3)	2452.2 (2793.7)	.122	.285
Creatinine (mg/dL)	1.3 (0.5)	1.3 (0.4)	.334	1.3 (0.6)	1.3 (0.6)	.955	.881
eGFR (mL/min)	58.5 (23.2)	56.8 (20.9)	.549	54.4 (21.9)	59.7 (24.7)	.746	.367

BMI, body mass index; BPM, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular filtrated rate; FCM, ferric carboxymaltose; Fe, Iron; Hb, hemoglobin; HR, heart rate; ID, iron deficiency; LVEF, left ventricular ejection fraction; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood pressure; TSAT, transferrin saturation.

18 patients were excluded from the analysis for incomplete data.

The correct dose was defined according to weight and Hb³. Functional ID was defined as ferritin < 100³.